Epidermal growth factor receptor (EGFR) mutation is one of the common actionable mutations in advanced NSCLC which is predictive of treatment response to tyrosine kinase inhibitors (TKIs)[3, 4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.